Download PDF
Semin Liver Dis 2005; 25(2): 125-132
DOI: 10.1055/s-2005-871192
Published in 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Genetic Profiling of Human Hepatocellular Carcinoma

Ju-Seog Lee1 , 3 , Snorri S. Thorgeirsson2 , 3
  • 1CRTA Fellow, Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • 2Chief, Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • 3Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Further Information

Publication History

Publication Date:
25 May 2005 (online)

    Permissions and Reprints

ABSTRACT

The underlying molecular basis for the heterogeneity in human liver cancer, hepatocellular carcinoma (HCC), is largely unknown. As with most other human cancers, the heterogeneous nature of HCC has hampered both treatment and prognostic predictions. Global gene expression profiling of human cancers is a promising new technology for refining the diagnosis and prognosis of HCC as well as for identifying potential therapeutic targets. Improved molecular characterization of HCC from gene expression profiling studies will undoubtedly improve the prediction of treatment responses, improve the selection of treatments for specific molecular subtypes of HCC, and ultimately improve the clinical outcome of HCC patients. We review the recent advances in gene expression profiling of HCC and discuss the biological and clinical insights obtained from these studies.

KEYWORDS

Hepatocellular carcinoma (HCC) - DNA microarray - gene expression profile - comparative functional genomics

REFERENCES

  • 1 Bruix J, Boix L, Sala M, Llovet J M. Focus on hepatocellular carcinoma.  Cancer Cell. 2004;  5 215-219
    CrossrefPubMedGoogle Scholar
  • 2 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362 1907-1917
    CrossrefPubMedGoogle Scholar
  • 3 Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma.  Nat Genet. 2002;  31 339-346
    CrossrefPubMedGoogle Scholar
  • 4 Lee J S, Thorgeirsson S S. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets.  Gastroenterology. 2004;  127 S51-S55
    CrossrefPubMedGoogle Scholar
  • 5 Ramaswamy S. Translating cancer genomics into clinical oncology.  N Engl J Med. 2004;  350 1814-1816
    CrossrefPubMedGoogle Scholar
  • 6 Alizadeh A A, Eisen M B, Davis R E et al.. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.  Nature. 2000;  403 503-511
    CrossrefPubMedGoogle Scholar
  • 7 Beer D G, Kardia S L, Huang C C et al.. Gene-expression profiles predict survival of patients with lung adenocarcinoma.  Nat Med. 2002;  8 816-824
    PubMedGoogle Scholar
  • 8 Bittner M, Meltzer P, Chen Y et al.. Molecular classification of cutaneous malignant melanoma by gene expression profiling.  Nature. 2000;  406 536-540
    CrossrefPubMedGoogle Scholar
  • 9 Roepman P, Wessels L F, Kettelarij N et al.. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas.  Nat Genet. 2005;  37 182-186
    PubMedGoogle Scholar
  • 10 Valk P J, Verhaak R G, Beijen M A et al.. Prognostically useful gene-expression profiles in acute myeloid leukemia.  N Engl J Med. 2004;  350 1617-1628
    CrossrefPubMedGoogle Scholar
  • 11 van't Veer L J, Dai H, van de Vijver M J et al.. Gene expression profiling predicts clinical outcome of breast cancer.  Nature. 2002;  415 530-536
    CrossrefPubMedGoogle Scholar
  • 12 Heller M J. DNA microarray technology: devices, systems, and applications.  Annu Rev Biomed Eng. 2002;  4 129-153 , Epub; 2002 Mar 22:129-153
    CrossrefPubMedGoogle Scholar
  • 13 Liang P, Pardee A B. Analysing differential gene expression in cancer.  Nat Rev Cancer. 2003;  3 869-876
    CrossrefPubMedGoogle Scholar
  • 14 Liang P, Pardee A B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction.  Science. 1992;  257 967-971
    PubMedGoogle Scholar
  • 15 Diatchenko L, Lau Y F, Campbell A P et al.. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries.  Proc Natl Acad Sci USA. 1996;  93 6025-6030
    CrossrefPubMedGoogle Scholar
  • 16 Lisitsyn N, Lisitsyn N, Wigler M. Cloning the differences between two complex genomes.  Science. 1993;  259 946-951
    PubMedGoogle Scholar
  • 17 Velculescu V E, Zhang L, Vogelstein B, Kinzler K W. Serial analysis of gene expression.  Science. 1995;  270 484-487
    CrossrefPubMedGoogle Scholar
  • 18 Schena M, Shalon D, Davis R W, Brown P O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray.  Science. 1995;  270 467-470
    PubMedGoogle Scholar
  • 19 Brenner S, Johnson M, Bridgham J et al.. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays.  Nat Biotechnol. 2000;  18 630-634
    PubMedGoogle Scholar
  • 20 Bruix J, Llovet J M. HCC surveillance: who is the target population?.  Hepatology. 2003;  37 507-509
    CrossrefPubMedGoogle Scholar
  • 21 Calvet X, Bruix J, Gines P et al.. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients.  Hepatology. 1990;  12 753-760
    CrossrefPubMedGoogle Scholar
  • 22 Chevret S, Trinchet J C, Mathieu D et al.. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire.  J Hepatol. 1999;  31 133-141
    CrossrefPubMedGoogle Scholar
  • 23 Okuda K, Ohtsuki T, Obata H et al.. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.  Cancer. 1985;  56 918-928
    CrossrefPubMedGoogle Scholar
  • 24 Pugh R N, Murray-Lyon I M, Dawson J L et al.. Transection of the oesophagus for bleeding oesophageal varices.  Br J Surg. 1973;  60 646-649
    CrossrefPubMedGoogle Scholar
  • 25 Tan C K, Law N M, Ng H S, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation.  J Clin Oncol. 2003;  21 2294-2298
    CrossrefPubMedGoogle Scholar
  • 26 CLIP investigators . A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.  Hepatology. 1998;  28 751-755
    CrossrefPubMedGoogle Scholar
  • 27 Chen X, Cheung S T, So S et al.. Gene expression patterns in human liver cancers.  Mol Biol Cell. 2002;  13 1929-1939
    CrossrefPubMedGoogle Scholar
  • 28 Kim B Y, Lee J G, Park S et al.. Feature genes of hepatitis B virus-positive hepatocellular carcinoma, established by its molecular discrimination approach using prediction analysis of microarray.  Biochim Biophys Acta. 2004;  1739 50-61
    PubMedGoogle Scholar
  • 29 Neo S Y, Leow C K, Vega V B et al.. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach.  Hepatology. 2004;  39 944-953
    CrossrefPubMedGoogle Scholar
  • 30 Xu X R, Huang J, Xu Z G et al.. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver.  Proc Natl Acad Sci USA. 2001;  98 15089-15094
    CrossrefPubMedGoogle Scholar
  • 31 Anders R A, Yerian L M, Tretiakova M et al.. cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis.  Am J Pathol. 2003;  162 991-1000
    PubMedGoogle Scholar
  • 32 Delpuech O, Trabut J B, Carnot F et al.. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma.  Oncogene. 2002;  21 2926-2937
    CrossrefPubMedGoogle Scholar
  • 33 Iizuka N, Oka M, Yamada-Okabe H et al.. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection.  Lancet. 2003;  361 923-929
    CrossrefPubMedGoogle Scholar
  • 34 Lee J S, Thorgeirsson S S. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer.  Hepatology. 2002;  35 1134-1143
    CrossrefPubMedGoogle Scholar
  • 35 Okabe H, Satoh S, Kato T et al.. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression.  Cancer Res. 2001;  61 2129-2137
    PubMedGoogle Scholar
  • 36 Paradis V, Bieche I, Dargere D et al.. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index.  Am J Pathol. 2003;  163 733-741
    CrossrefPubMedGoogle Scholar
  • 37 Smith M W, Yue Z N, Korth M J et al.. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers.  Hepatology. 2003;  38 1458-1467
    PubMedGoogle Scholar
  • 38 Smith M W, Yue Z N, Geiss G K et al.. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma.  Cancer Res. 2003;  63 859-864
    PubMedGoogle Scholar
  • 39 Ye Q H, Qin L X, Forgues M et al.. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.  Nat Med. 2003;  9 416-423
    CrossrefPubMedGoogle Scholar
  • 40 Lee J S, Chu I S, Heo J et al.. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.  Hepatology. 2004;  40 667-676
    CrossrefPubMedGoogle Scholar
  • 41 Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges.  Cell. 2002;  108 135-144
    CrossrefPubMedGoogle Scholar
  • 42 Klausner R D. Studying cancer in the mouse.  Oncogene. 1999;  18 5249-5252
    CrossrefPubMedGoogle Scholar
  • 43 Ellwood-Yen K, Graeber T G, Wongvipat J et al.. Myc-driven murine prostate cancer shares molecular features with human prostate tumors.  Cancer Cell. 2003;  4 223-238
    CrossrefPubMedGoogle Scholar
  • 44 Lee J S, Chu I S, Mikaelyan A et al.. Application of comparative functional genomics to identify best-fit mouse models to study human cancer.  Nat Genet. 2004;  36 1306-1311
    CrossrefPubMedGoogle Scholar
  • 45 Sweet-Cordero A, Mukherjee S, Subramanian A et al.. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.  Nat Genet. 2005;  37 48-55
    PubMedGoogle Scholar
  • 46 Wistuba I I, Gazdar A F, Minna J D. Molecular genetics of small cell lung carcinoma.  Semin Oncol. 2001;  28 3-13
    PubMedGoogle Scholar
  • 47 Beer D G, Kardia S L, Huang C C et al.. Gene-expression profiles predict survival of patients with lung adenocarcinoma.  Nat Med. 2002;  8 816-824
    PubMedGoogle Scholar
  • 48 Fan C Y, Pan J, Usuda N et al.. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism.  J Biol Chem. 1998;  273 15639-15645
    CrossrefPubMedGoogle Scholar
  • 49 Rao M S, Lalwani N D, Watanabe T K, Reddy J K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.  Cancer Res. 1984;  44 1072-1076
    PubMedGoogle Scholar
  • 50 Reddy J K, Lalwai N D. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans.  Crit Rev Toxicol. 1983;  12 1-58
    PubMedGoogle Scholar
  • 51 Gonzalez F J, Peters J M, Cattley R C. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.  J Natl Cancer Inst. 1998;  90 1702-1709
    CrossrefPubMedGoogle Scholar
  • 52 Calvisi D F, Factor V M, Ladu S, Conner E A, Thorgeirsson S S. Disruption of β-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice.  Gastroenterology. 2004;  126 1374-1386
    CrossrefPubMedGoogle Scholar
  • 53 Sargent L M, Zhou X, Keck C L et al.. Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver.  Am J Pathol. 1999;  154 1047-1055
    PubMedGoogle Scholar
  • 54 Calvisi D F, Factor V M, Loi R, Thorgeirsson S S. Activation of β-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade.  Cancer Res. 2001;  61 2085-2091
    PubMedGoogle Scholar
  • 55 Hsu H C, Jeng Y M, Mao T L et al.. β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.  Am J Pathol. 2000;  157 763-770
    CrossrefPubMedGoogle Scholar
  • 56 Mao T L, Chu J S, Jeng Y M et al.. Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.  J Pathol. 2001;  193 95-101
    CrossrefPubMedGoogle Scholar
  • 57 Wong C M, Fan S T, Ng I O. β-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance.  Cancer. 2001;  92 136-145
    CrossrefPubMedGoogle Scholar
  • 58 Laurent-Puig P, Legoix P, Bluteau O et al.. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis.  Gastroenterology. 2001;  120 1763-1773
    CrossrefPubMedGoogle Scholar
  • 59 Yarden Y, Sliwkowski M X. Untangling the ErbB signalling network.  Nat Rev Mol Cell Biol. 2001;  2 127-137
    CrossrefPubMedGoogle Scholar
  • 60 Cohen M H, Williams G A, Sridhara R et al.. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839, Iressa) tablets.  Clin Cancer Res. 2004;  10 1212-1218
    CrossrefPubMedGoogle Scholar
  • 61 Kitano H. Cancer robustness: tumour tactics.  Nature. 2003;  426 125
    CrossrefPubMedGoogle Scholar
  • 62 McNeil C. Herceptin raises its sights beyond advanced breast cancer.  J Natl Cancer Inst. 1998;  90 882-883
    CrossrefPubMedGoogle Scholar
  • 63 le Coutre P, Mologni L, Cleris L et al.. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.  J Natl Cancer Inst. 1999;  91 163-168
    CrossrefPubMedGoogle Scholar
  • 64 Paez J G, Janne P A, Lee J C et al.. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.  Science. 2004;  304 1497-1500
    CrossrefPubMedGoogle Scholar
  • 65 Lynch T J, Bell D W, Sordella R et al.. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2004;  350 2129-2139
    CrossrefPubMedGoogle Scholar

Snorri S ThorgeirssonM.D. Ph.D. 

Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute

National Institutes of Health, 37 Convent Drive, Building 37

Room 4146, Bethesda, MD 20892-4262

Email: snorri_thorgeirsson@nih.gov

      >